TY - JOUR
T1 - A novel animal model to study non-spontaneous bisphosphonates osteonecrosis of jaw
AU - Biasotto, Matteo
AU - Chiandussi, Silvia
AU - Zacchigna, Serena
AU - Moimas, Silvia
AU - Dore, Franca
AU - Pozzato, Gabriele
AU - Cavalli, Fabio
AU - Zanconati, Fabrizio
AU - Contardo, Luca
AU - Giacca, Mauro
AU - Di Lenarda, Roberto
PY - 2010/1/1
Y1 - 2010/1/1
N2 - J Oral Pathol Med (2010) 39: 390-396 The aim of this study was to evaluate a novel animal model of bisphosphonates-associated osteonecrosis, which realistically recapitulates the same pathological human condition. Five Wistar rats were given intravenous zoledronic acid 0.04 mg once a week for 5 weeks. After 2 weeks, the animals underwent the extraction of an upper molar, producing a 4 mm-diameter bone defect on the same site. After 7 weeks from the extraction, the animals were clinically examined and a bone scintigraphy was carried out. After an additional week, the rats were killed and both Computerized Tomography and histological analysis were performed. Five rats, not treated with zoledronic acid and exposed to the same surgical treatment, were used as controls. At 7 weeks after the extraction, all the rats treated with zoledronic acid showed expansion of the defect and bone exposure. These features were confirmed by bone scintigraphy. The rats of the control group demonstrated epithelialization of the bone defect and a normal uptake of the contrast medium during the scan. The Computerized Tomography scan disclosed irregularity of the cortical margin and bone destruction, which were not evident in the control group. On microscopy, the samples showed necrotic bone, loss of osteocytes and peripheral resorption without inflammatory infiltrate, while the controls showed normal bone healing. The rat treated with zoledronic acid can be considered a novel, reliable and reproducible animal model to understand better the pathophysiology of osteonecrosis of the jaw and to develop a therapeutic approach.
AB - J Oral Pathol Med (2010) 39: 390-396 The aim of this study was to evaluate a novel animal model of bisphosphonates-associated osteonecrosis, which realistically recapitulates the same pathological human condition. Five Wistar rats were given intravenous zoledronic acid 0.04 mg once a week for 5 weeks. After 2 weeks, the animals underwent the extraction of an upper molar, producing a 4 mm-diameter bone defect on the same site. After 7 weeks from the extraction, the animals were clinically examined and a bone scintigraphy was carried out. After an additional week, the rats were killed and both Computerized Tomography and histological analysis were performed. Five rats, not treated with zoledronic acid and exposed to the same surgical treatment, were used as controls. At 7 weeks after the extraction, all the rats treated with zoledronic acid showed expansion of the defect and bone exposure. These features were confirmed by bone scintigraphy. The rats of the control group demonstrated epithelialization of the bone defect and a normal uptake of the contrast medium during the scan. The Computerized Tomography scan disclosed irregularity of the cortical margin and bone destruction, which were not evident in the control group. On microscopy, the samples showed necrotic bone, loss of osteocytes and peripheral resorption without inflammatory infiltrate, while the controls showed normal bone healing. The rat treated with zoledronic acid can be considered a novel, reliable and reproducible animal model to understand better the pathophysiology of osteonecrosis of the jaw and to develop a therapeutic approach.
KW - Animal model
KW - Bisphosphonates
KW - Bone
KW - Jaws
KW - Osteonecrosis
UR - http://www.scopus.com/inward/record.url?scp=77951272653&partnerID=8YFLogxK
U2 - 10.1111/j.1600-0714.2009.00878.x
DO - 10.1111/j.1600-0714.2009.00878.x
M3 - Article
C2 - 20202091
AN - SCOPUS:77951272653
SN - 0904-2512
VL - 39
SP - 390
EP - 396
JO - Journal of Oral Pathology and Medicine
JF - Journal of Oral Pathology and Medicine
IS - 5
ER -